Sleep

New literature review data suggests doxazosin is related to less incident hypotension than prazosin, while providing clinical benefit, in PTSD patients with condition-related nightmares.

This sleep month in review features positive pipeline updates and treatments for improved sleep quality.

A new study found intensive topical therapy improves deep sleep and REM sleep for patients with psoriasis and atopic dermatitis after 2 weeks.

Topline data from the SURMOUNT-OSA studies provide insight into the effects of tirzepatide in OSA with obesity, with Lilly disclosing plans for a regulatory submission mid-year.

A new study explored increased health care utilization of children among several specific sleep disorders, race, and age.

A new study found patients with a BMI of 32 to 35 have lower odds of responding to the hypoglossal nerve stimulation for OSA compared to patients with a lower BMI.

This sleep month in review highlights the 6 top sleep pieces in March, from FDA news, topline data, and pieces exploring how daylight savings and long COVID impact sleep.

A phase 2 trial found KP1077 provides clinically meaningful benefits for idiopathic hypersomnia.

A new study found sleep and emotional well-being are impacted days before women get their period.

The SYMPHONY trial found reboxetine can significantly reduce cataplexy, excessive daytime sleepiness, cognitive impairment, depression, and anxiety for patients with narcolepsy.

With limited CBTi-trained psychologists, investigators assessed the effectiveness of a self-guided digital CBTi as another option, so people don’t have to turn to pills.

More than half of the participants were identified as insomnia sleepers and nappers, two suboptimal sleep patterns linked with an increased risk of a chronic condition.

After 5 years, laparoscopic Roux-en-Y gastric bypass cured OSA in 55.1% of patients, and only 20% of patients still had moderate or severe OSA.

Now, 4 years since the start of the pandemic, how has sleep been impacted? Sleep experts provide their perspective.

FDA issued a Complete Response Letter to Vanda Pharmaceuticals stating tasimelteon for treating insomnia cannot be approved in its current form due to identified deficiencies.

Results of a new analysis underscore the significance of sleep health in mitigating type 2 diabetes risk, revealing that even an optimal diet may not fully offset the negative impact of inadequate sleep.

Our February 2024 month-in-review recaps research on Long COVID’s effect on sleep, Black older adults’ poor sleep quality being linked to executive function decline, among other findings.

In time for daylight savings time starting on March 10, sleep experts weigh in on the harms of the daylight savings transition, such as increased risks for cardiovascular events, car accidents, and mortality.

Cancer patients with behavioral health disorders, such as substance abuse, eating disorders, and sleep disorders have a 7.76% increase in health care costs, a new study found.

A new study found only 15% of people sleep the recommended 7 – 9 hours for ≥ 5 nights per week.

After observing for sex differences, plant-based diet indices were associated with lower odds of OSA risk in males than females.

A new study found a greater sleep apnea risk was linked to verbal episodic memory decline and worse sleep quality was linked to executive function decline.

A new study found patients with Parkinson’s disease have a lower daytime light exposure with a mean light intensity of 201.1 lux than controls with a light intensity of 337.7 lux.

A new study for women with ≥ 4 hours a day of sedentary behavior had an increased risk of OSA but not for women with < 4 hours of sedentary behavior.

A new study found non-hospitalized COVID-19 survivors from a Vietnam general population had a 76.1% prevalence of insomnia, with 22.8% of respondents with insomnia scoring for severe insomnia.